Journal of Infection
Volume 60, Issue 5 , Pages 320-330 , May 2010

Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: A meta-analysis

  • Xiao-yan Yang

      Affiliations

    • Chinese Evidence-Based Medicine Center/The Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
    • ,
  • Qun-fei Chen

      Affiliations

    • Chinese Evidence-Based Medicine Center/The Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
    • ,
  • Xiao-hua Cui

      Affiliations

    • Chinese Evidence-Based Medicine Center/The Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
    • ,
  • Yu Yu

      Affiliations

    • West China Medical School, Sichuan University, Chengdu 610041, Sichuan Province, China
    • ,
  • You-ping Li

      Affiliations

    • Chinese Evidence-Based Medicine Center/The Chinese Cochrane Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 28 85423040; fax: +86 28 85422253.

,Accepted 6 February 2010.

References 

  1. Stanford JL. Improving on BCG. APMIS. 1991;99:103–113
  2. Li XM, Wang GZ, Zhao GF, Liu Y, Shen XB, Zhuang YH, et al. The effect of synthesis of nitrogen oxides of murine peritoneal macrophages by preparations of M. vaccea. J Chin Antituberc Assoc. 1996;18(3):122–124
  3. Wang GZ, Zhao GF, Li XM, Liu Y, Shen XB, Zhuang YH, et al. The effect of immunoregulation of preparation of Mycobacterium vaccea by nitrogen oxide. Chin J Tuberc Respir Dis. 1996;19(3):140–142
  4. Abou-Zeid C, Gares MP, Inwald J, Janssen R, Zhang Y, Young DB, et al. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun. 1997;65:1856–1862
  5. Hernandez-Pando F, Pavon L, Arriaga K, Orozco H, Madrid-Marina V, Rook G. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun. 1997;65:3317–3327
  6. Skinner MA, Yuan S, Prestidge R, Chuk D, Watson JD, Tan PL. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun. 1997;65:4525–4530
  7. Stanford JL, Bahr GM, Rook GA, Shaaban MA, Chugh TD, Gabriel M, et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle. 1990;71:87–93
  8. Stanford JL, Bahr GM, Byass P, Corrah T, Dowlate Y, Lucas S, et al. A modern approach to the immunotherapy of tuberculosis. Bull Int Union Tuberc. 1990;65:27–29
  9. Zhuang YH, Li XM, Li GL, Wang GZ, Zhao GF. The studies on the effect of proliferative response of peripheral blood lymphocyte of healthy persons by preparations of M. vaccea. Acta Microbiol Sin. 1995;35(4):292–297
  10. Stanford JL, Cordess G, Rook GA, Barnass S, Lucas S. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis. Vaccine. 1990;8:525–530
  11. WHO tuberculosis research and development. WHO/TB/91.62 WHO; 1991;
  12. National Cooperation Group on Clinical Study of Mycobacterium Vaccae Vaccine . The immunotherapeutic effect of Mycobacterium vaccae vaccine on initially treated pulmonary tuberculosis. Chin J Tuberc Respir Dis. 2001;24(1):43–47
  13. Luo YA, Lu SH, Guo SL, Liu ZC, Huang XC, Chen XH, et al. Effects of M. vaccea vaccine on treatment of refractory pulmonary tuberculosis. J Clin Pulmon Med. 2000;5(1):21–24
  14. Wang Q, Zhang J, Huang SP, Ma YP, Wu Q. Mycobacterium vaccae vaccine as an adjunctive therapy for relapsing and multidrug resistant tuberculosis: meta analysis. China Pharm. 2008;19(11):838–841
  15. Fan MY, Chen XR, Wang K, Mao H, Feng YL, Tang XY, et al. Adjuvant effect of Mycobacterium vaccae on treatment of recurrent treated pulmonary tuberculosis: a meta-analysis. Chin J Evid-based Med. 2007;7(6):449–455
  16. de Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst Rev. 2003;1:CD001166
  17. Marsh BJ, von Reyn C Fordham, Arbeit Robert D, Morin Paul. Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae. Am J Med Sci. 1997;313:377–383
  18. von Reyn C Fordham, Marsh Bryan J, Waddell Richard, Lein A David, Tvaroha Susan, Morin Paul, et al. Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus-positive subjects in the United States after a five-dose schedule of Mycobacterium vaccae vaccine. Clin Infect Dis. 1998;27:1517–1520
  19. Johnson Daniel, Waddell Richard D, Pelton Steven I, Jaeger Anna S, Modlin John F, Yogev Ram, et al. Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection. Vaccine. 1999;17:2583–2587
  20. Waddell Richard D, Chintu Chifumbe, David Lein A, Zumla Alimuddin, Karagas Margaret R, Baboo KS, et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis. 2000;30(Suppl. 3):S309–S315
  21. Vuola Jenni M, Matti AR, Bernard Cole, Annika J, Tvaroha Susan, Terhi R, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS. 2003;17(16):2351–2355
  22. Jin XH, Liu YD, Guo HL, Li ZJ, Cheng XH, Zhuang YH. Influence of Mycobacterium vaccae on humoral immunity of the PPD positive cases and its significance. J Chin Antituberc Assoc. 2000;22(1):18–19
  23. Liu YD, Jin XH, Li ZJ, Cheng XH, Sun B, Zhuang YH, et al. A study on preventive effect of Mycobacterium vaccae vaccine for M. tuberculosis infected people. J Chin Antituberc Assoc. 2000;22(4):220–221
  24. Sun YZ, Gu MH, Li SZ, Su J, Liu Z, Fu XD. Preventive effects of Mycobacterium vaccae vaccine in PPD strong positive cases. Chin J Biol. 2004;17(4):249–250
  25. Huang CM, Huang QW, Qin YQ. Clinical observation on prevention of diabetes complicated with pulmonary tuberculosis by Mycobacterium vaccae vaccine. Acta Acad Med Militar Tert. 2004;26(16):1476–1478
  26. Wang MJ, Zhao SX. Clinical study on prevention of diabetes complicated with tuberculosis by Mycobacterium vaccae. J Clin Pulmon Med. 2008;13(4):439–441
  27. Zhang WT, Sun XL, Ding KL, Shen YP, Wu LH. A study of the immunological intervention effects of injectable Mycobacterium vaccae on Mycobacterium tuberculosis infected people. Hebei Med J. 2008;30(8):1239
  28. Huang MP, Shi YQ, Zhu XP. The effects of Mycobacterium vaccae in preventing pulmonary tuberculosis relapse in the aged people. Zhejiang Prev Med. 2008;20(9):84
  29. Sun ZP, Liu H, Li J, Tao LF, Gui XD. Cell-mediated immunological mechanism of Mycobacterium vaccae in the prophylactic treatment for latent tuberculosis infection. J Clin Pulmon Med. 2009;14(2):158–161
  30. Horsburgh CR. Immunologic evaluation of persons infected with immunodeficiency virus. Clin Lab Med. 1989;9:393–403
  31. Ainslie GM, Solomon JA, Bateman ED. Lymphocyte and lymphocyte subset numbers in blood and in bronchoalveolar lavage and pleural fluid in various forms of human pulmonary tuberculosis at presentation and during recovery [J]. Thorax. 1992;47(7):513–518
  32. Boom WH. The role of T cell subsets in M. tuberculosis infection. Infect Agents Dis. 1996;5:73–81
  33. Boom WH, Canaday David H, Fulton Scott A, Gehring Adam J, Rojas Roxana E, Torres Marta. Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis. 2003;83:98–106
  34. Yu C-T, Wang C-H, Huang T-J, Lin H-C, Kuo H-P. Relation of bronchoalveolar lavage T lymphocyte subpopulations to rate of regression of active pulmonary tuberculosis. Thorax. 1995;50:869–874
  35. Huang JY, He YS, Lu YH. Tuberculosis and HIV/AIDS. Henan J Prev Med. 2008;19(3):224–226
  36. Yan BY. Progress on the relationship of HIV infection, AIDS and tuberculosis. Chin J Tuberc Respir Dis. 1996;19(6):329–332
  37. Zheng XM. The clinic impact of tuberculosis on the course of HIV-infected patients with a CD4+ lymphocyte count. Med J Chin People Health. 2005;17(4):135–136
  38. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA. 1995;273:220–226
  39. Barnes PF, Bloch AB, Davidson P, Snider D. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 1991;324:1644–1650
  40. Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis. 1992;15:540–547
  41. von Reyn CF, Clements J, Mann JM. HIV infection and routine childhood immunization. Lancet. 1987;2:669–672
  42. Talbot EA, Perkins MD, Silva SFM, Frothingham R. Disseminated bacilli Calmette–Guerin disease after vaccination: case report and review. Clin Infect Dis. 1997;24:1139–1146

PII: S0163-4453(10)00044-7

doi: 10.1016/j.jinf.2010.02.005

Journal of Infection
Volume 60, Issue 5 , Pages 320-330 , May 2010

Article Tools

* Image Usage & Resolution